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Objective: To investigate the humoral immune status and the effect of antibiotic treatment in Bulgarian patients with 
early Lyme disease. 
Methods: A total of 34 early Lyme disease patients was examined, 16 with erythema migrans and 18 with non-specific 
systemic symptoms. Serum samples from all patients and from 12 healthy controls were tested for total 
immunoglobulins (IgG, IgA and IgM), hemolytic activity of complement (CHso) and immune complexes (ICs). The patients 
were treated with doxycycline (100 mg orally, twice daily for 10 to 15 days, in one or two courses). 
Results: The patients showed significantly increased IC levels (P<O.OI for patients with erythema migrans and P<O.OOl 
for patients with non-specific symptoms). There were no significant changes in the levels of total hemolytic complement 
and total immunoglobulins (IgG, IgA and IgM). The clinical outcome was satisfactory in 21 of the 34 patients (61.8%) 
after treatment with doxycycline for 10 to 15 days. The rest of the patients (38.2%) failed to respond to the therapy, and 
continued to report various complaints, such as arthralgia, myalgia, paresthesia, headache, fatigue or recurrent rash. 
All of these had elevated levels of IC. After a second course of treatment with the same antibiotic regimen these patients 
had resolution of symptoms (12 patients) or improvement (1 patient). 
Conclusions: Immunologic investigation may be useful in determining treatment strategy in Lyme disease. Elevated 
IC levels may indicate a need for more prolonged antibiotic therapy. 
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Lyme hsease or Lyme borreliosis is a tick-borne chronic 
infectious multisystem disease, caused by the spirochete 
Borrelia burgdorferi [ 11. There is considerable variation in 
the course, which is usually divided into three stages 
[l]. The initial c h c a l  manifestations (stage 1 or early 
Lyme disease) include a characteristic skin rash called 
erythema migrans (EM) and non-specific systemic 
symptoms such as regional lymphadenopathy, myalgia, 
fever and headache. In the second stage of Lyme disease 
(weeks or months after the tick bite) carhac and 
neurologic symptoms are encountered. In the most 
advanced third stage of the infection, beginning 
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months or years after the tick bite, joint dysfimction 
can occur. 
The pathogenesis of Lyme disease involves the 
ability of the spirochete to enter the circulation and to 
persist in the infected host for prolonged periods [l-31. 
The role of the immune response in the pathogenesis 
of Lyme disease has not been completely elucidated. 
Despite the high concentration of protective antibodies 
and circulating T-cells, the immune response itself 
cannot guarantee eradication of B. burgdorferi [4,5]. 
Sometimes the symptoms persist in patients after 
antibiotic treatment [6]. Immunologic measurements 
might be usefd in evaluation of the treatment of Lyme 
disease patients. 
Recently, B. burgdoferi has been found in Ixodes 
ricinus ticks (infection rate 41.5%) collected in Bulgaria 
[7]. Lyme disease patients at Werent stages have been 
diagnosed and treated. 
The present study was undertaken to investigate 
various aspects of the humoral immune status and the 
effect of antibiotic treatment in Bulgarian patients with 
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early Lyme disease. Circulating immune complexes 
(ICs), hemolytx activity of complement (CH50) and 
total immunoglobulins (IgM, IgG and IgA) in serum 
were determined. 
PATIENTS AND METHODS 
From June 1989 to May 1991 34 patients with early 
Lyme borreliosis were examined and treated at the 
Hospital of Infectious Diseases in Sofia, Bulgaria. The 
patients were aged fiom 12 to 60 years (me&an 38 
years); 21 were female and 13 were male. Of the 34 
patients, 16 had EM, the best clinical marker for the 
illness. Ten of these had EM accompanied by minor 
constitutional symptoms, such as fever, arthralgia or 
headache. Eighteen of the 34 patients had early Lyme 
disease without EM. They revealed non-specific sys- 
temic symptoms such as fever, regional lymphadeno- 
pathy, musculoskeletal &scornfort, headache or fatigue. 
The dagnosis of Lyme disease was based on 
detection of specific antiborrelial antibody in serum as 
described by Noeva et al., who used two methods: 
indirect micro-ELISA and immunodot test [8]. Only 
patients with a positive serologic test for specific 
antibodies were included in the analysis. In addition, 26 
of the 34 patients cecalled tick bite 15 to 60 days before 
the development of symptoms. All the patients were 
treated with doxycycline (doxycycline hydrochloride), 
100 mg twice daily, for 10 to 15 days, in one or two 
courses. In order to assess the response to therapy, 
repeated physical examinations and clinical evaluations 
were made afier starting the treatment, and 1 month 
afier completion. 
Serologic analysis 
Serum samples were obtained before treatment, or very 
early in treatment. Sera &om 12 healthy subjects were 
tested as controls. Blood was allowed to clot at room 
temperature for 1 h, and after centrifugation (2000g 
for 10 min) the serum was separated and &quoted. The 
serum samples for testing the immunoglobulins and 
CH50 were stored at -20°C. The serum samples for 
determination of ICs were tested immediately, without 
fieezing. 
ICs were measured using the polyethylene glycol 
method [9].  Total IgM, IgA and IgG concentrations 
were determined by radial immunodi&sion [lo]. 
CH50 titration was performed using sheep red blood 
cells coated with anti-sheep red cell antibodies [ll]. 
Statistical methods 
Student’s t-test was used to determine the statistical 
si@icance of the established differences. In all cases, a 
P value of less than or equal to 0.05 was considered to 
indicate statistical significance. 
RESULTS 
Serum immunoglobulin levels 
Elevation of IgG antibodies above normal was found in 
two of 16 patients with EM and in five of 18 patients 
with non-specific systemic symptoms. IgM antibodies 
were elevated in one patient with EM and in two 
patients with non-specific systemic symptoms. In al l  
34 patients the levels of total IgA were in the normal 
range. The mean values of total immunoglobulins (I&, 
IgA and IgM) are shown in Table 1. There was no 
statistically sigmficant difference between patients with 
Lyme disease and healthy subjects. 
Hemolytic activity of complement 
The hemolytic activity of complement varied among 
the patients. Two of the 18 patients with non-specific 
systemic symptoms, and four of the patients with 
EM, had values of CH50 above the range of normal 
individuals. Three of the 16 patients with EM and six 
of the 18 patients with non-specific systemic symptoms 
showed lower complement hemolytic activity com- 
pared with the controls. The mean CH50 values for all 
Lyme disease patients are presented in Table 1. There 
were no statistically significant differences between the 
patients and the controls. 
Immune complexes 
Thrteen of the 16 patients with EM and 12 of the 18 
patients with non-specific systemic symptoms showed 
elevated levels of IC. The circulating IC levels in the 
patients with Lyme disease were significantly higher 
than in the controls (Table 1). The mean IC value in 
patients with EM was 137.1 U/mL as against 71.7 
U/mL in controls (WO.01). The patients with non- 
specific systemic symptoms had a mean IC value of 
116.4 U/mL, sigrufcantly higher than in the controls 
(P<O.OOl). 
Clinical course and treatment 
The response to therapy was not uniform. Treatment 
with doxycycline (100 mg orally, twice daily for 10 
to 15 days) was effective in 21 of the 34 patients. A 
satisfactory clinical response, with resolution of EM 
rash and other clinical signs and symptoms, was 
achieved and the patient remained asymptomatic 
during the 1-month post-treatment follow-up period. 
The rest of the patients (13) failed to respond to the 
therapy. After treatment, two patients (one with EM 
and one with non-specific systemic symptoms) con- 
tinued to complain of fatigue, headache, and myalgia; 
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Table 1 Serum immunologic parameters in patients with early Lyme disease (mean value C SD) 
clinical 
character IgG W) IgA (g/L) IgM WL) IC (U/mL) CHso (HU/mL) 
EM 
(n=16) 12.425.6 1.950.6 1.32 0.6 137.1579.9 106.8t32.3 
NSS 
(n=18) 13.826.1 1.620.6 1.220.5 116.4235.7 90.8L17.5 
Controls 
(n=12) 12.56223 2.0+0.7 1.2t0.4 71.72 13.5 96.8L5.1 
NSS =non-specific systemic symptoms. 
Significant differences were noted as follows. IC: P<O.01 between patients with EM and controls. IC: P<O.OOl between patients with NSS 
and controls. 
five patients with EM and three with non-specific 
systemic symptoms complained of mild arthralgia 
and myalgia; one patient with non-specific systemic 
symptoms developed peripheral neuropathy; and two 
patients with EM had a recurrent rash. All these 
patients required retreatment because of the persistent 
illness. The second course of doxycycline (200 mg dady 
for 10 to 15 days) was effective in these patients: 12 had 
resolution of symptoms and one patient with arthralgia 
showed improvement. All 13 patients with persisting 
symptoms (eight patients with EM and five patients 
with non-specific systemic symptoms) had elevated IC 
levels in the initial stage of treatment. Patients with 
satisfactory outcome (without persisting symptoms after 
antibiotic treatment) varied regarding IC levels observed 
in the initial stage of treatment: five of eight patients 
with EM had elevated IC levels, as did seven of 13 
patients with non-specific systemic symptoms. There is 
a tendency to have higher levels of IC in patients with 
persisting symptoms compared with patients with- 
out persisting symptoms or relapse, especially in EM 
patients (162.5283.5 as against 111.7?61 U/mL), but 
there is not a statistically significant difference. 
DISCUSSION 
Daerent immunologic abnormalities have been re- 
corded in patients with Lyme disease, and this has 
suggested a possible involvement of the specific or 
innate host responses in the pathogenesis of the disease 
[1,4,12,13]. In order to find out whether some humoral 
immunologic parameters had a prognostic value for the 
treatment and the clinical outcome of the disease we 
measured total immunoglobulins, IC levels and the 
hemolytic activity of complement before or early in 
treatment in patients with early Lyme disease. 
Because of the essential bactericidal activity of 
antibody and complement in the human host defense 
against Gram-negative bacteria, we undertook an 
analysis of serum IgG, IgA and IgM antibodies and the , v  
hemolytic activity of complement. It is known that 
anti-B. btrrgdoferi immunoglobulin responses develop 
slowly and then persist [4,5]. Some studies have found 
signs of polyclonal B-cell activation (elevated total 
serum immunoglobulins) with a correlation between 
total serum IgM concentration and severity of clinical 
signs and symptoms and outcome [1,12-141. In our 
study seven patients showed elevation of IgG, and three 
patients showed elevation of IgM antibodies. However, 
these differences were not significant (Table 1). 
Complement activation is not a consistent feature 
of clinical Lyme disease [ 1,14,15]. We observed a broad 
range of hemolytic activity of complement among 
the 34 patients: 55.9% had normal values, 26.5% low 
activity and 17.6% higher activity of complement. 
Generally, there was no significant hfference between 
values of complement activity in the patients with early 
Lyme disease and in the controls. This variability in 
the studied patients could be explained by differences 
between B. burgdo~eri strains and/or different host 
defense factors. 
It -has been established that in Lyme disease [l] 
immune complexes are formed, and their possible role 
in the pathogenesis of the disease has been considered. 
ICs were determined before or early in treatment. We 
have established that a significant increase in the level 
of the IC exists in the patients with EM (81.25%, 
WO.01) and in patients with non-specific systemic 
symptoms (66.7%, P<O.OOl) .  
As doxycycline has been recommended as an 
appropriate antibiotic for the treatment of early Lyme 
disease [6,16], we have used it for the therapy of 
our patients. The initial course of treatment (200 mg 
daily for 10 to 15 days) was effective in 61.8% of 
the 34 patients. The rest of the patients (13) developed 
persisting symptoms such as arthralgia, myalgia and 
relapse of EM signs. A second course with the same 
drug and in the same regimen was successful. Elevation 
of IC levels was seen in all these patients, but there 
was not a statisticallv significant difference fi-om the 
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IC levels in patients without persisting symptoms. 
However, in unsuccessfully treated patients with EM 
there was more prominent elevation of IC levels in 
comparison with patients with EM, which benefits 
&om one course ofdoxycycline (162.52-183.5 U/mL as 
against 116.3 k49.3 U/mL). Therefore, an assumption 
can be made that EM patients with more prominent IC 
levels need more prolonged antibiotic treatment. 
In order to c h i @  the precise role of IC and other 
factors of humoral immunity in the pathogenesis of 
Lyme disease further investigations are necessary. 
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